We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more
Cover

Psychopharmacology

Fourth Edition

Jerry Meyer

Publication Date - May 2022

ISBN: 9781605359878

816 pages
Hardcover
8.5â x 10.875â inches

In Stock

Retail Price to Students: $136.95

Unique in its breadth of coverage ranging from historical accounts of drug use to clinical and preclinical behavioral studies, Psychopharmacology is appropriate for undergraduates studying the relationships between the behavioral effects of psychoactive drugs and their mechanisms of action.

Description

Unique in its breadth of coverage ranging from historical accounts of drug use to clinical and preclinical behavioral studies, Psychopharmacology is appropriate for undergraduates studying the relationships between the behavioral effects of psychoactive drugs and their mechanisms of action.

  • Chapter-opening vignettes foster student engagement
  • Up-to-date and outstanding coverage of current research
  • Breakout boxes present novel, and, in some cases, controversial topics for special discussion. Box themes include History of Psychopharmacology; Pharmacology in Action; Clinical Applications; Of Special Interest; and The Cutting Edge
  • The book is extensively illustrated with full-color photographs and line art depicting important concepts and experimental data
  • Section Summaries highlight key concepts from the section of text just read
  • Chapter-ending Recommended Readings offer suggestions for further study
  • Enhanced e-Book provides an interactive learning pathway through the content
  • End-of-chapter study questions to further aid students
    Meyer, Psychopharmacology and it's accompanying enhanced ebook provide engaging features like self-study questions, and clinical case studies, cutting edge research, and applied pharmacology to keep students focused on the content, while providing the scientific depth, breadth, and rigor required for the course.

  • New to this Edition

    • NEW Enhanced e-Book with self-Assessment questions, animations, flashcards, and more!
    • NEW Learning Objectives
    • Critical thinking/active learning case studies that integrate concepts
    • Content updates in every chapter: CR Chapters 1 and 2: New Case Study Boxes link pharmacology and neuroscience to clinical practices CR Chapter 3: Expanded coverage of oxytocin including use in treating autism disorders CR Chapter 4: New techniques including genetic engineering and AI, and how they are used CR Chapters 5-8: These chapters are about neurotransmitter systems. New emphasis in these chapters on clinical applications of drugs that target neurotransmitters CR Chapter 9: New theories and mechanisms of drug addiction CR Chapters 10-17: All on different recreational drugs CR Chapter 11: Updated coverage of the opioid epidemic and treatments CR Chapter 13: More coverage of cigarettes and vaping CR Chapter 14: New coverage of cannabis legalization and therapeutic applications of CBD CR Chapter 15: New coverage of psychedelic drugs and use in treatment of mood and trauma related disorders
    • CR Chapters 16-20: On neurobiology of neuropsychiatric and neurodegenerative disorders and the drugs used to treat them CR Chapters 17 and 18: On classis pharmacotherapies, but also NEW coverage of use of non-traditional substances (like LSD) in treatment CR Chapter 19: New treatment possibilities for schizophrenia are covered CR Chapter 20: Covers new trial, therapies, tools, etc. for all neurodegenerative disorders, including coverage of emerging new systems that can be used for diagnosis

    Features

    • Enhanced ebook with integrated animations, web-links, flashcards, and self-assessment questions

    About the Author(s)

    Jerrold S. Meyer is Professor Emeritus of Psychology and former Director of the interdeparmental Neuroscience and Behavior Program at the University of Massachusetts, Amherst.

    Andrew M. Farrar is a Lecturer in the College of Natural Sciences at the University of Massachusetts Amherst and previously worked as a research scientist in academia and the pharmaceutical industry.

    Dominik Biezonski is a Senior Scientist in Preclinical Development at Prevail Therapeutics, which focuses on developing gene therapies for neurodegenerative diseases.

    Jennifer R. Yates is the Assistant Provost for Faculty Development, Teaching, & Learning, Director of the Center for Faculty Excellence, and Professor of Psychological Science at Lander University

    Table of Contents

      Chapter 1. Principles of Pharmacology
      Chapter 2. Structure and Function of the Nervous System
      Chapter 4. Methods of Research in Psychopharmacology
      Chapter 5. Catecholamines
      Chapter 6. Serotonin
      Chapter 7. Acetylcholine
      Chapter 8. Glutamate and GABA
      Chapter 9. Drug Abuse and Addiction
      Chapter 10. Alcohol
      Chapter 11. The Opioids
      Chapter 12. Psychomotor Stimulants: Cocaine, Amphetamine, and Related Drugs
      Chapter 13. Nicotine and Caffeine
      Chapter 14. Marijuana and the Cannabinoids
      Chapter 15. Hallucinogens, PCP, and Ketamine
      Chapter 16. Inhalants, GHB, and Anabolic-Androgenic Steroids
      Chapter 17. Disorders of Anxiety and Impulsivity and the Drugs Used to Treat These Disorders
      Chapter 18. Affective Disorders: Antidepressants and Mood Stabilizers
      Chapter 19. Schizophrenia: Antipsychotic Drugs
      Chapter 20. Neurodegenerative Diseases, by Jennifer R. Yates, Lander University